导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 36.41% | 78/4773 |
| 近一周 | -0.16% | 952/5465 |
| 近一月 | -1.78% | 1291/5421 |
| 近一季 | -17.11% | 4556/5231 |
| 近半年 | 28.72% | 82/4920 |
| 近一年 | 53.39% | 73/4394 |
| 近两年 | 234.99% | 59/2954 |
| 近三年 | 226.58% | 11/2253 |
| 成立以来 | 78.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.46% 1541/4961 |
75.87% 204/5312 |
- - |
- - |
| 2025 | 91.56% 51/4813 |
-2.45% 2889/3635 |
5.82% 538/4076 |
73.66% 15/4524 |
6.85% 335/4813 |
| 2024 | 22.93% 360/3463 |
0.59% 952/2808 |
9.00% 60/3014 |
9.49% 2697/3129 |
2.39% 950/3463 |
| 2023 | 15.29% 37/2656 |
22.84% 124/2280 |
7.86% 23/2385 |
-12.05% 2103/2515 |
-1.07% 281/2655 |
| 2022 | -34.89% 1722/2207 |
-26.06% 1787/1919 |
3.38% 1162/2016 |
-18.32% 1696/2113 |
4.28% 567/2208 |
| 2021 | 6.29% 520/1822 |
-15.15% 1189/1255 |
19.84% 154/1330 |
-9.43% 1179/1466 |
15.41% 62/1822 |
| 2020 | - - |
- - |
- - |
-9.72% 1133/1164 |
-1.29% 1100/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华中证5G通信主题ETF联接A VS. 长安沪深300非周期A(740101) |